Medexus Pharmaceuticals (MDP) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
24 Sep, 2026Opening remarks and agenda
Chair welcomed shareholders, directors, and guests, outlined procedural details, and confirmed voting would be conducted online with questions accepted via the platform.
Four formal business matters were set: presentation of financials, election of directors, reappointment of auditors, and approval of an amendment to the long-term incentive plan.
Financial performance review
Consolidated financial statements for years ended March 31, 2026 and 2025, and the auditor's report, were presented and made available to shareholders.
Board and executive committee updates
Seven directors were nominated and elected to serve until the next annual meeting or until successors are appointed.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Medexus Pharmaceuticals
- GRAFAPEX growth lifted Q2 results; FY2027 revenue guidance remains $30M–$32M.MDP
Q2 2027 - GRAFAPEX anchors a focused heme-onc strategy, with FY revenue guided at $30M–$32M.MDP
Planet MicroCap Showcase: Toronto 2026 - GRAFAPEX commercialization and a robust rare disease portfolio drive strong US-led revenue growth.MDP
Investor presentation - Record GRAFAPEX growth drove a 16.3% revenue increase and strong Q1 2027 financials.MDP
Q1 2027 - Treosulfan's U.S. launch is set to double revenue and boost margins, driving strong future growth.MDP
Bloom Burton & Co. Healthcare Investor Conference 2025 - GRAFAPEX momentum offsets legacy declines, with FY2027 revenue projected at $30–$32M.MDP
Q4 2026 - GRAFAPEX adoption and margin gains offset portfolio headwinds and support future growth.MDP
Q3 2026 - Q2 revenue fell but net income and EBITDA rose; treosulfan US launch prep underway.MDP
Q2 2025 - Record revenue and EBITDA achieved; key regulatory reviews and leadership changes underway.MDP
Q4 2024